FacebookTwitterGoogle+RedditEmail

Can Wyeth Fool American Women Twice?

by MARTHA ROSENBERG

Can Wyeth win back the 40 million Premarin and Prempro users it’s lost since 2002–along with $1 billion a year in profits–with a new menopause drug?

Or will the once-bitten women who have filed more than 5,000 law suits claiming the hormones gave them cancer feel fooled twice?

Pristiq, a serotonin/norepinephrine reuptake inhibitor (SNRI), is a metabolite of Wyeth’s antidepressant Effexor XR–which netted $3.7 billion in 2006–and an unabashed patent extender since Effexor XR goes off patent in 2010.

In February Pristiq was approved by the FDA for the treatment of adults with major depressive disorder but its launch as the first non-hormonal treatment for menopausal symptoms is what Wyeth hopes will fill the Premarin/Prempro/Effexor black hole to the tune of $2 billion a year.

Unfortunately, instead of a green light to market Pristiq for menopause last July, the FDA–also once bitten after Vioxx, Avandia and Vytroin–said to Wyeth not so fast.

Why did two women in the study group taking Pristiq have heart attacks and three need procedures to repair clogged arteries compared with none taking placebo it wanted to know? How can Wyeth assure long term safety when 604 of the 2,158 test subjects took Pristiq for only six months and 318 for a year or more? And what about serious liver complications seen in the studies?

Nor do drug industry insiders on the chatroom cafepharma sound like they’re scooping up Wyeth stock.

“Pristiq is not a good drug by any standard,” wrote one anonymous poster. “We tried to get 100 mg approved as the standard dose. But our patients got so sick that they could care less about the efficacy. They just couldn’t tolerate the drug long enough to see any improvement.”

Like longer than six months?

“No study exists showing any anti-depressant including Pristiq works any better than a placebo for reducing hot flashes, which are subjective anyway and only last a few minutes long at worst,” wrote another anonymous poster. “That is a heavy price to pay to take a heavy duty drug 24/7 for a few minutes of daily relief that a sugar pill also provides. FDA is crazy (or bought) if they allow this unproven drug travesty on the market.”

A third poster predicted women wouldn’t trade, “hot flashes for decreased libido, nausea, increased blood pressure and incredible withdrawal issues,” found with Pristiq. “Women and their physicians are not as gullible as they were back in the Premarin days.”

Even psychiatrist Daniel Carlat who wrote an expose for the New York Times magazine called Dr. Drug Rep last year about his experiences as a Wyeth paid spokesman, is dissing Pristiq.

“Every patient who takes Effexor produces Pristiq in their own body, at no additional charge,” he writes in a blog article called Top 5 Reasons to Forget About Pristiq.

Moreover Wyeth’s own investigator on the major Pristiq trials, Dr. Michael Liebowitz, admits it is “not a revolutionary drug” writes Carlat.

Of course you can’t blame a one trick company that cut its teeth on the Feminine Forever idea that age in women is a disease that needs treating for churning the demographics. Especially as it lays off 1,200 US workers, closes manufacturing plants and fights for its life.

Was it Wyeth’s fault that the hormone “therapy” it pushed for decades actually increases breast cancer by 26 percent, heart attacks by 29 percent, stroke by 41 percent and doubles the risk of blood clots and dementia?

But if US women embrace a major psychiatric drug with possible liver and heart complication side effects after the hormone hoax–manufactured by the same company and at four times the cost of Prempro/Premarin, $4 per day–

Fool me twice–?

MARTHA ROSENBERG is staff cartoonist on the Evanston Roundtable. She can be reached at mrosenberg@evmark.org

 

Your Ad Here
 

 

 

 

 

More articles by:

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

Weekend Edition
February 16, 2018
Friday - Sunday
Jeffrey St. Clair
American Carnage
Paul Street
Michael Wolff, Class Rule, and the Madness of King Don
Andrew Levine
Had Hillary Won: What Now?
David Rosen
Donald Trump’s Pathetic Sex Life
Susan Roberts
Are Modern Cities Sustainable?
Joyce Nelson
Canada vs. Venezuela: Have the Koch Brothers Captured Canada’s Left?
Geoff Dutton
America Loves Islamic Terrorists (Abroad): ISIS as Proxy US Mercenaries
Mike Whitney
The Obnoxious Pence Shows Why Korea Must End US Occupation
Joseph Natoli
In the Post-Truth Classroom
John Eskow
One More Slaughter, One More Piece of Evidence: Racism is a Terminal Mental Disease
John W. Whitehead
War Spending Will Bankrupt America
Dave Lindorff
Trump’s Latest Insulting Proposal: Converting SNAP into a Canned Goods Distribution Program
Robert Fantina
Guns, Violence and the United States
Robert Hunziker
Global Warming Zaps Oxygen
John Laforge
$1.74 Trillion for H-bomb Profiteers and “Fake” Cleanups
CJ Hopkins
The War on Dissent: the Specter of Divisiveness
Peter A. Coclanis
Chipotle Bell
Anders Sandström – Joona-Hermanni Mäkinen
Ways Forward for the Left
Wilfred Burchett
Vietnam Will Win: Winning Hearts and Minds
Tommy Raskin
Syrian Quicksand
Martha Rosenberg
Big Pharma Still Tries to Push Dangerous Drug Class
Jill Richardson
The Attorney General Thinks Aspirin Helps Severe Pain – He’s Wrong
Mike Miller
Herb March: a Legend Deserved
Ann Garrison
If the Democrats Were Decent
Renee Parsons
The Times, They are a-Changing
Howard Gregory
The Democrats Must Campaign to End Trickle-Down Economics
Sean Keller
Agriculture and Autonomy in the Middle East
Ron Jacobs
Re-Visiting Gonzo
Eileen Appelbaum
Rapid Job Growth, More Education Fail to Translate into Higher Wages for Health Care Workers
Ralph Nader
Shernoff, Bidart, and Echeverria—Wide-Ranging Lawyers for the People
Chris Zinda
The Meaning of Virginia Park
Robert Koehler
War and Poverty: A Compromise with Hell
Mike Bader – Mike Garrity
Senator Tester Must Stop Playing Politics With Public Lands
Kenneth Culton
No Time for Olympic Inspired Nationalism
Graham Peebles
Ethiopia: Final Days of the Regime
Irene Tung – Teófilo Reyes
Tips are for Servers Not CEOs
Randy Shields
Yahoomans in Paradise – This is L.A. to Me
Thomas Knapp
No Huawei! US Spy Chiefs Reverse Course on Phone Spying
Mel Gurtov
Was There Really a Breakthrough in US-North Korea Relations?
David Swanson
Witness Out of Palestine
Binoy Kampmark
George Brandis, the Rule of Law and Populism
Dean Baker
The Washington Post’s Long-Running Attack on Unions
Andrew Stewart
Providence Public School Teachers Fight Back at City Hall
Stephen Cooper
Majestic Meditations with Jesse Royal: the Interview
David Yearsley
Olympic Music
FacebookTwitterGoogle+RedditEmail